Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Increased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 16.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 509,459 shares of the company's stock after buying an additional 71,200 shares during the quarter. Price T Rowe Associates Inc. MD owned 1.77% of Krystal Biotech worth $79,812,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Hsbc Holdings PLC boosted its position in Krystal Biotech by 195.2% during the 4th quarter. Hsbc Holdings PLC now owns 4,519 shares of the company's stock worth $718,000 after purchasing an additional 2,988 shares during the period. Avoro Capital Advisors LLC boosted its position in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after buying an additional 6,600 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Krystal Biotech by 7,944.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,999 shares of the company's stock valued at $1,096,000 after buying an additional 6,912 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Krystal Biotech by 4.7% during the 4th quarter. MetLife Investment Management LLC now owns 14,997 shares of the company's stock valued at $2,349,000 after buying an additional 680 shares during the period. Finally, S Squared Technology LLC lifted its position in Krystal Biotech by 26.6% during the 4th quarter. S Squared Technology LLC now owns 95,215 shares of the company's stock worth $14,916,000 after acquiring an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by company insiders.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $0.47 during trading on Friday, hitting $166.16. 228,173 shares of the stock were exchanged, compared to its average volume of 294,547. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34. The stock's fifty day moving average is $174.92 and its 200 day moving average is $171.25. The stock has a market cap of $4.80 billion, a PE ratio of 55.57 and a beta of 0.79.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech's revenue was up 116.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.30 earnings per share. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on KRYS shares. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 price objective on the stock. Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Citigroup boosted their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, HC Wainwright lifted their price target on shares of Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a report on Monday, April 28th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and an average price target of $222.71.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).